» Articles » PMID: 25705619

Current and Emerging Therapy for Celiac Disease

Overview
Specialty General Medicine
Date 2015 Feb 24
PMID 25705619
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

At present, strict and lifelong gluten-free diet is the only effective treatment for celiac disease. Even small amounts of gluten (50 mg/day) can be immunogenic; therefore all food and food items and drugs that contain gluten and its derivatives must be eliminated completely from the diet. While prescribing gluten-free diet is easy; the key to the success is the dietary counseling by a nutrition specialist and maintenance of adherence to GFD by the patient. In recent times, a number of targets to halt the process of immunological injury have been explored to find out alternative treatment for celiac disease. These targets include exploration of ancient wheat if they are less immunogenic, intra-luminal digestion of gluten using prolylendopeptidases, pretreatment of whole gluten with bacterial-derived peptidase before ingestion; prevention of passage of immunogenic peptides through the tight junctions such as zonulin antagonists, Blocking of HLA-DQ2 to prevent binding of immunogenic peptides, inhibition of transglutaminase 2, immune-modulation, and induction of tolerance to gluten using gluten tolerizing vaccines, use of gluten-sequestering polymers, use of anti-inflammatory drugs (glucocorticoids, budesonides) and anti-cytokines such as anti TNF-α, and anti-interleukin-15. While many of these targets are still in the pre-clinical phase, some of them including zonulin antagonist and endopeptidases have already reached phase II and phase III clinical trials. Furthermore, while these targets appear very exciting; they at best are likely to be used as adjunctive therapy rather than a complete replacement for gluten-free diet.

Citing Articles

Rapid discovery of Transglutaminase 2 inhibitors for celiac disease with boosting ensemble machine learning.

Wichka I, Lai P Comput Struct Biotechnol J. 2024; 23:3669-3679.

PMID: 39498152 PMC: 11532751. DOI: 10.1016/j.csbj.2024.10.019.


Celiac disease: Pathogenesis, disease management and new insights into the herbal-based treatments.

Mittal P, Arora D, Parashar S, Goyal R, Khan A, Chopra H Narra J. 2024; 3(2):e147.

PMID: 38454981 PMC: 10919711. DOI: 10.52225/narra.v3i2.147.


Fracture risk among children and adolescents with celiac disease: a nationwide cohort study.

Zacay G, Weintraub I, Regev R, Modan-Moses D, Levy-Shraga Y Pediatr Res. 2023; 95(1):386-392.

PMID: 37749190 DOI: 10.1038/s41390-023-02826-5.


Novel Therapies for Celiac Disease: A Clinical Review Article.

Ghazanfar H, Javed N, Lee S, Shaban M, Cordero D, Acherjee T Cureus. 2023; 15(5):e39004.

PMID: 37323330 PMC: 10263194. DOI: 10.7759/cureus.39004.


Study of effect of gluten-free diet on vitamin D levels and bone mineral density in celiac disease patients.

Verma A, Lata K, Khanna A, Singh R, Sachdeva A, Jindal P J Family Med Prim Care. 2022; 11(2):603-607.

PMID: 35360767 PMC: 8963631. DOI: 10.4103/jfmpc.jfmpc_1190_21.


References
1.
Gillett H, Arnott I, McIntyre M, Campbell S, Dahele A, Priest M . Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology. 2002; 122(3):800-5. DOI: 10.1053/gast.2002.31874. View

2.
Utech M, Ivanov A, Samarin S, Bruewer M, Turner J, Mrsny R . Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol Biol Cell. 2005; 16(10):5040-52. PMC: 1237102. DOI: 10.1091/mbc.e05-03-0193. View

3.
Larche M, Wraith D . Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med. 2005; 11(4 Suppl):S69-76. DOI: 10.1038/nm1226. View

4.
Lee A, Newman J . Celiac diet: its impact on quality of life. J Am Diet Assoc. 2003; 103(11):1533-5. DOI: 10.1016/j.jada.2003.08.027. View

5.
Cagno R, De Angelis M, Auricchio S, Greco L, Clarke C, De Vincenzi M . Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol. 2004; 70(2):1088-96. PMC: 348803. DOI: 10.1128/AEM.70.2.1088-1096.2004. View